 ROCKVILLE, Md.--BUSINESS WIRE--GlycoMimetics, Inc. Nasdaq: GLYC today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a poster presentation at the American Association of Cancer Research AACR 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. The study demonstrates that GMI-1757 significantly improved anti- 